Explanipedia

Long-term efficacy of Mindfulness Based Stress Reduction on Depression and Anxiety, Symptoms and Distress, Health Status, Coping Capacity and Immune Response in Breast Cancer Survivors: A longitudinal Randomized Controlled Trial Open

Elisabeth Kenne Sarenmalm, Salmir Nasic, Anne Gitte Loft, Lena Mårtensson, Per Karlsson · 2025

Purpose This 5-year longitudinal randomized controlled trial explored the long-term efficacy of a MBSR intervention for psychological and biological response in breast cancer survivors. Methods A total of 166 women were randomly assigned i…

Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT Open

Clara Mistegaard, Murat Torğutalp, Anne Gitte Loft, Steffen Thiel, Valeria Ríos Rodríguez , et al. · 2025

Objective To investigate complement system activation and complement protein levels in relation to radiographic progression in axial spondyloarthritis (axSpA) within a longitudinal randomised controlled trial (RCT) of radiographic axSpA pa…

Advanced combination therapy with tofacitinib and biologic agents for psoriasis and psoriatic arthritis: A case series Open

Cathrine Dawn Büttner Elgaard, Trine Bay Laurberg, Jørgen Agnholt, Anne Gitte Loft, Kasper Fjellhaugen Hjuler · 2025

The treatment of psoriatic disease is frequently complex, and many patients do not respond to the available therapies. While novel therapies like biologics and janus kinase (JAK) inhibitors have been utilized individually to treat psoriati…

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial Open

Line Uhrenholt, Mads Engell Refstrup Sørensen, Jan Sørensen, Anne Estrup Olesen, Robin Christensen , et al. · 2025

Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study Open

Stylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, Merete Lund Hetland, Gareth T. Jones , et al. · 2025

Exploring associations of single nucleotide polymorphisms in ERAP1 and ERAP2 with susceptibility to multiple immune-mediated inflammatory diseases Open

Sofie Jørgensen, Trine Bertelsen, Lasse Kronborg, Anders Dige, Trine Bay Laurberg , et al. · 2025

POS1154 IMPACT OF PRIOR TNF INHIBITOR TREATMENT ON THE TIME TO ACHIEVE LOW DISEASE ACTIVITY AND THE DURATION OF LOW DISEASE ACTIVITY IN 17,858 EUROPEAN PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING A TNF INHIBITOR OR AN IL-17A INHIBITOR Open

J. Heberg, Stylianos Georgiadis, Marc Tey, Anne Gitte Loft, B. Michelsen , et al. · 2025

POS0762 REDEFINING BASDAI CUT-OFFS: IMPLICATIONS FOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG ELIGIBILITY IN AXIAL SPONDYLOARTHRITIS Open

Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, Tore K Kvien, M. Shoae Kazemi , et al. · 2025

POS1204 DISEASE ACTIVITY-GUIDED TAPERING OF BIOLOGICS INCLUDING BIOSIMILARS IS COST-EFFECTIVE IN PATIENTS WITH INFLAMMATORY ARTHRITIS: SECONDARY ANALYSES OF THE RANDOMISED BIODOPT TRIAL Open

Line Uhrenholt, Mads Engell Refstrup Sørensen, Jan Sørensen, Anne Estrup Olesen, R. Christensen , et al. · 2025

POS1189 ONE-YEAR SAFETY OUTCOMES IN >2,100 DANISH PATIENTS WITH ARTHRITIS TREATED WITH BIOSIMILAR INFLIXIMAB (GP1111) IN ROUTINE CARE Open

Hafsah Nabi, K.Y. Jensen, Robert W. Westermann, Oliver Hendricks, Dorte Vendelbo Jensen , et al. · 2025

OP0181 DAPSA AND DAPSA28 INTERNAL CONSTRUCT VALIDITY ASSESSED BY CONFIRMATORY FACTOR ANALYSIS AND OTHER PSYCHOMETRIC TESTS BASED ON EUROPEAN DATA Open

Jan Brauner, Karl Bang Christensen, B. Michelsen, Anne Gitte Loft, S.H. Rasmussen , et al. · 2025

Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Open

Brigitte Michelsen, Mikkel Østergaard, Michael J. Nissen, Adrian Ciurea, Burkhard Möller , et al. · 2025

The findings highlight substantial variability in healthcare set-ups for biologic/targeted synthetic DMARD use in psoriatic arthritis and axial spondyloarthritis across Europe and their association with socioeconomic status and drug costs.…

Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased Open

Christos Polysopoulos, Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Almut Scherer, Daniela Di Giuseppe , et al. · 2025

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network Open

Marion Pons, Stylianos Georgiadis, Merete Lund Hetland, Z. Faizy Ahmadzay, Simon Horskjær Rasmussen , et al. · 2025

Objective In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloar…

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries Open

Adrian Ciurea, Seraphina Kissling, Andrea Götschi, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen , et al. · 2025

Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis Open

Stylianos Georgiadis, Marion Pons, Simon Horskjær Rasmussen, Merete Lund Hetland, Louise Linde , et al. · 2025

Objectives We aimed to compare various methods for imputing disease activity in longitudinally collected observational data of patients with axial spondyloarthritis (axSpA). Methods We conducted a simulation study on data from 8583 axSpA p…

Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicentre RCT Open

Clara Mistegaard, Anne Troldborg, Murat Torğutalp, Anne Gitte Loft, Steffen Thiel , et al. · 2024

Objectives To investigate lectin pathway proteins (LPPs) and complement activation marker C3dg as biomarkers for disease activity and treatment response in a multicentre, randomized controlled trial of axial spondyloarthritis (axSpA) patie…

P56 Validation and comparison of the early arthritis for psoriatic patients questionnaire, the psoriasis epidemiology screening tool and the psoriatic arthritis uncluttered screening evaluation (PURE-4) in a Danish population Open

Cathrine Dawn Büttner Elgaard, Trine Bay Laurberg, René Østgård, Rick H. Hoyle, Anne Gitte Loft , et al. · 2024

Up to 30% of patients with psoriasis (PsO) develop psoriatic arthritis (PsA). National guidelines recommend screening patients with PsO for PsA; however, there is no consensus on the best-suited method. This study aims to validate and comp…

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis Open

Marion Pons, Stylianos Georgiadis, Mikkel Østergaard, Z. Faizy Ahmadzay, Bente Glintborg , et al. · 2024

This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMA…

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries Open

Lykke Midtbøll Ørnbjerg, Stylianos Georgiadis, Tore K Kvien, Brigitte Michelsen, Simon Horskjær Rasmussen , et al. · 2024

Objectives To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-of…

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial Open

Line Uhrenholt, Mads Engell Refstrup Sørensen, Karen B. Lauridsen, Kirsten Duch, Lene Dreyer , et al. · 2024

To evaluate tumour necrosis factor inhibitor (TNFi) drug-levels and presence of anti-drug antibodies (ADAb) in patients with inflammatory arthritis who taper TNFi compared to TNFi continuation. Patients with rheumatoid arthritis, psoriatic…

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study Open

Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Østergaard, Marion Pons, Brigitte Michelsen , et al. · 2024

Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secuk…

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response Open

AJ Mathew, Merete Lund Hetland, MP Pedersen, SH Rasmussen, Bente Glintborg , et al. · 2024

Entheseal assessments are only registered in a minority of patients with PsA in routine care. When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.

Exploring complement biomarkers in suspected axial spondyloarthritis Open

Clara Mistegaard, Anne Troldborg, Anne Gitte Loft, Steffen Thiel, Laura Spiller , et al. · 2024

Objectives To investigate lectin pathway proteins (LPPs) as biomarkers for axial spondyloarthritis (axSpA) in a cross-sectional cohort with a suspicion of axSpA, comprising newly diagnosed axSpA and chronic low back pain (cLBP) individuals…

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment Open

Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, L. Jacobsson, Michael J. Nissen , et al. · 2024

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice Open

Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, Brigitte Michelsen, Bente Glintborg , et al. · 2024

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care Open

Lykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, Simon Horskjær Rasmussen, L. Jacobsson , et al. · 2024

Objective To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across …

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey Open

Zohra F. Ahmadzay, J. Heberg, Jacob Brauner Jørgensen, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard , et al. · 2024

Objectives Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who have non-musculoskeletal manifestations (NMMs), various risk factors and comorbidities. International collaboration is …

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results from the Eurospa Research Collaboration Network Open

Lykke Midtbøll Ørnbjerg, Marion Pons, Stylianos Georgiadis, Merete Lund Hetland, Z. Faizy Ahmadzay , et al. · 2024

Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers Open

Helena Port, Frederik Voetmann Christiansen, Signe Holm Nielsen, Peder Frederiksen, Anne‐Christine Bay‐Jensen , et al. · 2024

Objective To explore the potential of a panel of ECM remodelling markers as endotyping tools for axial spondyloarthritis (axSpA) by separating patients into subtypes and investigate how they differ among each other in disease activity scor…

Anne Gitte Loft YOU? Author Swipe